石墨烯板塊拉昇 我國8英寸石墨烯晶圓亮相
格隆匯12月7日丨石墨烯板塊拉昇,寶泰隆、德爾未來雙雙漲停,華麗家族、碳元科技、方大炭素等個股跟漲。近日,中科院正式宣佈已研發出8英寸石墨烯單晶圓。該團隊甚至表示“不管在產品尺寸、產品質量方面均處於國際領先地位!”華創證券指出,石墨烯單晶圓要比傳統的硅晶圓在性能上提高了十倍以上,量產後勢必會讓半導體領域重新洗牌。事實上世界上有很多國家在研究該類型芯片,但能生產出8英寸石墨烯晶圓的目前只有中國,接下來中科院將進一步研究如何將石墨烯晶圓這一物質實現碳基芯片的量產,一旦實現這個目標,中國就能在芯片領域獲得全新的地位,從被動接受者搖身一變為規則制定者,硅基芯片在全球的壟斷地位會被全面打破。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.